Scholarlink

Background <p>Positron Emission Tomography (PET) imaging using 3’-deoxy-3’-[F-18] fluorothymidine (FLT) is a valuable non-invasive marker of tumor proliferation. However, variability in imaging protocols and quantitative analysis techniques hampers comparability across preclinical chemotherapy response studies.</p> Methods <p>To address this issue in preclinical studies, we evaluated two key areas: (1) imaging standardization (2) semi-quantitative analyses, including Standard Uptake Value (SUV) SUV(max) and SUV(mean), and percent injected (%ID)/g. Using standardized methods of animal handling, image acquisition, image reconstruction and analyses, we assessed multiple FLT uptake metrics in three responsive Patient-Derived Xenograft (PDX) models treated with temozolomide/berzosertib or cisplatin/berzosertib. Metrics included: %ID, SUVbw(max), SUVbw(mean) with a Region of Interest (ROI) threshold of 50% of the maximum value [SUVbw(mean-50%)], and the ratios tumor-to-tissue and tumor-to-liver. Statistical comparisons were made using Brown-Forsythe and Kruskal-Wallis ANOVA and unpaired two tailed t-test to assess cohort differences.</p> Results <p>Across models and timepoints, no statistical difference among analysis techniques were observed except for one outlier at day 3 in one vehicle cohort, likely due to variability in the normalization parameter. SUVbw(max) and SUVbw(mean-50%) showed the strongest ability to differentiate between vehicle and treated cohorts.</p> Conclusion <p>Semi-quantitative FLT PET metrics can be harmonized across preclinical studies, with caveats in understanding the normalization parameters, with SUV-based metrics preferred and that larger numbers of animals per cohort will be required to power (≥0.8) robust conclusions. These findings support FLT PET standardization in translational imaging.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of quantitative imaging analysis methods to evaluate murine [18F]FLT PET therapy response studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • J. D. Kalen,
  • J. L. Tatum,
  • P. M. Jacobs,
  • J. H. Doroshow

摘要

Background

Positron Emission Tomography (PET) imaging using 3’-deoxy-3’-[F-18] fluorothymidine (FLT) is a valuable non-invasive marker of tumor proliferation. However, variability in imaging protocols and quantitative analysis techniques hampers comparability across preclinical chemotherapy response studies.

Methods

To address this issue in preclinical studies, we evaluated two key areas: (1) imaging standardization (2) semi-quantitative analyses, including Standard Uptake Value (SUV) SUV(max) and SUV(mean), and percent injected (%ID)/g. Using standardized methods of animal handling, image acquisition, image reconstruction and analyses, we assessed multiple FLT uptake metrics in three responsive Patient-Derived Xenograft (PDX) models treated with temozolomide/berzosertib or cisplatin/berzosertib. Metrics included: %ID, SUVbw(max), SUVbw(mean) with a Region of Interest (ROI) threshold of 50% of the maximum value [SUVbw(mean-50%)], and the ratios tumor-to-tissue and tumor-to-liver. Statistical comparisons were made using Brown-Forsythe and Kruskal-Wallis ANOVA and unpaired two tailed t-test to assess cohort differences.

Results

Across models and timepoints, no statistical difference among analysis techniques were observed except for one outlier at day 3 in one vehicle cohort, likely due to variability in the normalization parameter. SUVbw(max) and SUVbw(mean-50%) showed the strongest ability to differentiate between vehicle and treated cohorts.

Conclusion

Semi-quantitative FLT PET metrics can be harmonized across preclinical studies, with caveats in understanding the normalization parameters, with SUV-based metrics preferred and that larger numbers of animals per cohort will be required to power (≥0.8) robust conclusions. These findings support FLT PET standardization in translational imaging.